EG20672A - Neuroprotective compounds - Google Patents
Neuroprotective compoundsInfo
- Publication number
- EG20672A EG20672A EG6795A EG6795A EG20672A EG 20672 A EG20672 A EG 20672A EG 6795 A EG6795 A EG 6795A EG 6795 A EG6795 A EG 6795A EG 20672 A EG20672 A EG 20672A
- Authority
- EG
- Egypt
- Prior art keywords
- pct
- sec
- date
- neuroprotective compounds
- pub
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Diabetes (AREA)
- Anesthesiology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Toxicology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Cosmetics (AREA)
- Saccharide Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Hydrogenated Pyridines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US18947994A | 1994-01-31 | 1994-01-31 |
Publications (1)
Publication Number | Publication Date |
---|---|
EG20672A true EG20672A (en) | 1999-11-30 |
Family
ID=22697514
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EG6795A EG20672A (en) | 1994-01-31 | 1995-01-28 | Neuroprotective compounds |
Country Status (27)
Country | Link |
---|---|
US (1) | US5744483A (ja) |
EP (1) | EP0741724B1 (ja) |
JP (1) | JP2866743B2 (ja) |
CN (1) | CN1048247C (ja) |
AT (1) | ATE183184T1 (ja) |
AU (1) | AU684568B2 (ja) |
BR (2) | BR9408506A (ja) |
CA (1) | CA2182101C (ja) |
CO (1) | CO4230161A1 (ja) |
CZ (1) | CZ286757B6 (ja) |
DE (1) | DE69420053T2 (ja) |
DK (1) | DK0741724T3 (ja) |
EG (1) | EG20672A (ja) |
ES (1) | ES2134361T3 (ja) |
FI (1) | FI113769B (ja) |
GR (1) | GR3031356T3 (ja) |
HU (1) | HU221633B1 (ja) |
IL (1) | IL112415A (ja) |
MY (1) | MY111623A (ja) |
NO (1) | NO309190B1 (ja) |
NZ (1) | NZ275151A (ja) |
PE (1) | PE43795A1 (ja) |
PL (1) | PL179448B1 (ja) |
RU (1) | RU2126404C1 (ja) |
TW (1) | TW449591B (ja) |
WO (1) | WO1995020587A1 (ja) |
ZA (1) | ZA95692B (ja) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2232059A1 (en) * | 1995-09-15 | 1997-03-20 | Bertrand Leo Chenard | Phenol derivatives with pharmaceutical activity |
TW498067B (en) * | 1996-07-19 | 2002-08-11 | Hoffmann La Roche | 4-hydroxy-piperidine derivatives |
EP1674087A1 (en) | 2000-10-02 | 2006-06-28 | Pfizer Products Inc. | Prophylactic use of n-methyl-d-aspartate (NMDA) antagonists |
ZA200108038B (en) * | 2000-10-02 | 2003-04-01 | Pfizer Prod Inc | Prophylactic use of n-methyl-d-asparrate (NMDA) antagonists. |
SE0100902D0 (sv) | 2001-03-15 | 2001-03-15 | Astrazeneca Ab | Compounds |
JP4864719B2 (ja) * | 2003-11-26 | 2012-02-01 | ファイザー・プロダクツ・インク | Gsk−3インヒビターとしてのアミノピラゾール誘導体 |
CA2628173A1 (en) | 2005-11-03 | 2007-05-10 | F. Hoffmann-La Roche Ag | Arylsulfonylchromans as 5-ht6 inhibitors indolylmaleimide derivatives as protein kinase inhibitors |
JP5047992B2 (ja) * | 2006-01-20 | 2012-10-10 | シェーリング コーポレイション | ガンマセクレターゼ阻害剤としての、炭素環および複素環アリールスルホン |
EP2522647B1 (en) * | 2011-05-10 | 2014-04-30 | DSM IP Assets B.V. | Process of separating chiral isomers of chroman compounds and their derivatives and precursors |
Family Cites Families (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3294804A (en) * | 1961-01-27 | 1966-12-27 | Sterling Drug Inc | 1-(3-hydroxy-3-phenylpropyl)-4-phenyl-4-propionoxy-piperidine |
FR5733M (ja) * | 1966-09-27 | 1968-01-22 | ||
GB1495526A (en) * | 1974-05-31 | 1977-12-21 | Beecham Group Ltd | Chroman derivatives |
US4016281A (en) * | 1975-02-22 | 1977-04-05 | Merck Patent Gesellschaft Mit Beschrankter Haftung | Tetralone and indanone compounds |
US4082755A (en) * | 1977-02-14 | 1978-04-04 | Janssen Pharmaceutica N.V. | 1-[(Diarylmethyl)aminoalkyl]piperidimes |
WO1980000152A1 (en) * | 1978-07-03 | 1980-02-07 | Sandoz Ag | 3-aminopropoxy-aryl derivates,preparation and use thereof |
US4358456A (en) * | 1980-05-03 | 1982-11-09 | John Wyeth & Brother Limited | Antipsychotic piperidinomethyl-indole derivatives |
DE3045688A1 (de) * | 1980-12-04 | 1982-07-08 | C.H. Boehringer Sohn, 6507 Ingelheim | Neue 8-arylalkyl-3-phenyl-3-nortropanole, deren saeureadditionssalze, diese enthaltende arzneimittel und verfahren zu ihrer herstellung |
ATE23718T1 (de) * | 1981-09-25 | 1986-12-15 | Beecham Group Plc | Benzopyran-verbindungen mit pharmazeutischer wirkung. |
EP0093534A1 (en) * | 1982-04-28 | 1983-11-09 | Beecham Group Plc | Novel chromanols |
GB8308064D0 (en) * | 1983-03-24 | 1983-05-05 | Beecham Group Plc | Active compounds |
FR2581993B1 (fr) * | 1985-05-14 | 1988-03-18 | Synthelabo | Derives de (benzoyl-4 piperidino)-2 phenyl-1 alcanols, leur preparation et leur application en therapeutique |
US4957928A (en) * | 1986-06-26 | 1990-09-18 | Ciba-Geigy Corporation | Hydrogenated 1-benzooxacycloalkylpyridinecarboxylic acid compounds |
US4968678A (en) * | 1988-02-19 | 1990-11-06 | Eli Lilly And Company | Tetrazole excitatory amino acid receptor antagonists |
FR2640266B2 (fr) * | 1988-07-12 | 1992-07-10 | Synthelabo | Derives de (hydroxy-1 piperidinyl-2 alkyl) indolones-2, quinoleinones-2, benzo(b)azepinones-2 et benzimidazolones-2, leur preparation et leur application en therapeutique |
US4968878A (en) * | 1989-02-07 | 1990-11-06 | Transitions Research Corporation | Dual bumper-light curtain obstacle detection sensor |
US4902695A (en) * | 1989-02-13 | 1990-02-20 | Eli Lilly And Company | Excitatory amino acid receptor antagonists |
SK279476B6 (sk) * | 1989-05-17 | 1998-11-04 | Pfizer | Deriváty 2-piperidino a 2-pyrolidino-1-alkanolov a |
WO1991012005A1 (en) * | 1990-02-06 | 1991-08-22 | Pfizer Inc. | Neuroprotective 3-piperidino-4-hydroxychroman derivatives and analogs |
US5192751A (en) * | 1992-07-24 | 1993-03-09 | Eli Lilly And Company | Use of competitive NMDA receptor antagonists in the treatment of urinary incontinence |
-
1994
- 1994-11-21 CN CN94194940A patent/CN1048247C/zh not_active Expired - Fee Related
- 1994-11-21 AU AU80663/94A patent/AU684568B2/en not_active Ceased
- 1994-11-21 CA CA002182101A patent/CA2182101C/en not_active Expired - Fee Related
- 1994-11-21 HU HU9602100A patent/HU221633B1/hu not_active IP Right Cessation
- 1994-11-21 WO PCT/IB1994/000365 patent/WO1995020587A1/en active IP Right Grant
- 1994-11-21 CZ CZ19962256A patent/CZ286757B6/cs not_active IP Right Cessation
- 1994-11-21 RU RU96117381A patent/RU2126404C1/ru not_active IP Right Cessation
- 1994-11-21 PL PL94315681A patent/PL179448B1/pl unknown
- 1994-11-21 DE DE69420053T patent/DE69420053T2/de not_active Expired - Fee Related
- 1994-11-21 NZ NZ275151A patent/NZ275151A/en unknown
- 1994-11-21 JP JP7519959A patent/JP2866743B2/ja not_active Expired - Lifetime
- 1994-11-21 US US08/687,542 patent/US5744483A/en not_active Expired - Fee Related
- 1994-11-21 ES ES94931668T patent/ES2134361T3/es not_active Expired - Lifetime
- 1994-11-21 DK DK94931668T patent/DK0741724T3/da active
- 1994-11-21 EP EP94931668A patent/EP0741724B1/en not_active Expired - Lifetime
- 1994-11-21 BR BR9408506A patent/BR9408506A/pt not_active Application Discontinuation
- 1994-11-21 AT AT94931668T patent/ATE183184T1/de not_active IP Right Cessation
- 1994-11-22 TW TW083110873A patent/TW449591B/zh active
-
1995
- 1995-01-18 PE PE1995259688A patent/PE43795A1/es not_active Application Discontinuation
- 1995-01-23 IL IL11241595A patent/IL112415A/xx not_active IP Right Cessation
- 1995-01-27 CO CO95003001A patent/CO4230161A1/es unknown
- 1995-01-27 MY MYPI95000224A patent/MY111623A/en unknown
- 1995-01-28 EG EG6795A patent/EG20672A/xx active
- 1995-01-30 BR BR9500380A patent/BR9500380A/pt not_active IP Right Cessation
- 1995-01-30 ZA ZA95692A patent/ZA95692B/xx unknown
- 1995-01-30 FI FI950403A patent/FI113769B/fi not_active IP Right Cessation
-
1996
- 1996-07-30 NO NO963186A patent/NO309190B1/no unknown
-
1999
- 1999-09-29 GR GR990402449T patent/GR3031356T3/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL113566A0 (en) | Use of certain methanebisphosphonic acid derivatives to prevent prosthesis loosening and prosthesis migration | |
HU9502193D0 (en) | Combination treatment for inhibiting bone loss | |
ZA974387B (en) | Use of p-aminophenol derivatives for the preparation of pharmaceutical compositions useful in the treatment of neurodegenerative diseases. | |
EG20672A (en) | Neuroprotective compounds | |
GR3033005T3 (en) | Application of riluzole in the treatment of mitochondrial diseases | |
NZ268110A (en) | Use of ropivacaine salt in pharmaceutical compositions for the treatment of pain with sensoric block and minimal motor blockage | |
EP0653936A1 (en) | USE OF 2- (4- (4-CHLOROPHENYL) CYCLOHEXYL] -3-HYDROXY-1,4-NAPHTOQUINONE IN THE TREATMENT OF CANCER. | |
NZ268914A (en) | Use of efaroxan and derivatives to prepare medicaments for treating neurodegenerative diseases especially alzheimer's disease | |
RU94044487A (ru) | Применение 2-фенил-3-ароилбензотиофенов для лечения мужского бесплодия | |
BG105289A (en) | The use of r(+)-alpha-(2,3-dimethoxyphenyl)-1-[2- (4-fluorophenyl)ethyl]-4-pip eridinemethanol for the treatment of sleep disorders | |
AU2796695A (en) | Pyrrolidine derivatives for the treatment of cholecystokinine and gastrine-related disorders |